NEW YORK (CNNMoney)
Onyx (ONXX), which develops cancer drugs and treatments, said Monday that Amgen's takeover bid of $120 a share undervalued the company. Onyx stock closed Friday at $86.82.
"We are actively exploring the potential to combine Onyx with another company as an option to create additional value for Onyx shareholders," said Onyx CEO N. Anthony Coles.
Related: Brutal June clouds stocks outlook for 2nd half
Shares of Onyx rose more than 6% last week on news of Amgen's offer. Overall, the stock has increased nearly 36% since last year.
Amgen (AMGN, Fortune 500) is a major player in biopharmaceuticals, and manufactures drugs for many conditions, including ones that counteract the effects of cancer treatments.
First Published: June 30, 2013: 2:36 PM ET
Anda sedang membaca artikel tentang
Onyx rejects Amgen's takeover bid
Dengan url
https://brokolsayuransehat.blogspot.com/2013/07/onyx-rejects-amgens-takeover-bid.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
Onyx rejects Amgen's takeover bid
namun jangan lupa untuk meletakkan link
Onyx rejects Amgen's takeover bid
sebagai sumbernya
0 komentar:
Posting Komentar